@article{5ccba244448f41da80600ecc8812a180,
title = "EEF-2 kinase is a critical regulator of Warburg effect through controlling PP2A-A synthesis",
abstract = "Cancer cells predominantly metabolize glucose by glycolysis to produce energy in order to meet their metabolic requirement, a phenomenon known as Warburg effect. Although Warburg effect is considered a peculiarity critical for survival and proliferation of cancer cells, the regulatory mechanisms behind this phenomenon remain incompletely understood. We report here that eukaryotic elongation factor-2 kinase (eEF-2K), a negative regulator of protein synthesis, has a critical role in promoting glycolysis in cancer cells. We showed that deficiency in eEF-2K significantly reduced the uptake of glucose and decreased the productions of lactate and adenosine triphosphate in tumor cells and in the Ras-transformed mouse embryonic fibroblasts. We further demonstrated that the promotive effect of eEF-2K on glycolysis resulted from the kinase-mediated restriction of synthesis of the protein phosphatase 2A-A (PP2A-A), a key factor that facilitates the ubiquitin-proteasomal degradation of c-Myc protein, as knockdown of eEF-2K expression led to a significant increase in PP2A-A protein synthesis and remarkable downregulation of c-Myc and pyruvate kinase M2 isoform, the key glycolytic enzyme transcriptionally activated by c-Myc. In addition, depletion of eEF-2K reduced the ability of the transformed cells to proliferate and enhanced the sensitivity of tumor cells to chemotherapy both in vitro and in vivo. These results, which uncover a role of the eEF-2K-mediated control of PP2A-A in tumor cell glycolysis, provide new insights into the regulation of the Warburg effect.",
author = "Y. Cheng and X. Ren and Y. Yuan and Y. Shan and L. Li and X. Chen and L. Zhang and Y. Takahashi and Yang, {J. W.} and B. Han and J. Liao and Y. Li and H. Harvey and A. Ryazanov and Robertson, {G. P.} and G. Wan and D. Liu and Chen, {A. F.} and Y. Tao and Yang, {J. M.}",
note = "Funding Information: We sincerely thank Dr Zhimin Lu (MD Anderson Cancer Center, USA) and Drs Jing Chen and Taro Hitosugi (Emory University School of Medicine) for PKM2 plasmids, Dr Christopher Proud (University of Southampton, UK) for eEF-2K plasmid and Dr Jayanta Debnath (University of California San Francisco, USA) for H-RasV12 retroviral plasmid. This work was supported by grants from the National Basic Research Program of China (973 Program) 2015CB910700 (to YC), 2014CB542400 (to AFC); the National Natural Science Foundation of China 81422051, 81472593 and 31401208 (to YC); the National Basic Research Program of China 2015CB553903 (to YT) and the National Natural Science Foundation of China 81372427 (to YT); the US Department of Defense BC103654 (to YC); and the US Public Health Service NIH/NCI R01CA135038 (to J-MY). Funding Information: This work was supported by grants from the National Basic Research Program of China (973 Program) 2015CB910700 (to YC), 2014CB542400 (to AFC); the National Natural Science Foundation of China 81422051, 81472593 and 31401208 (to YC); the National Basic Research Program of China 2015CB553903 (to YT) and the National Natural Science Foundation of China 81372427 (to YT); the US Department of Defense BC103654 (to YC); and the US Public Health Service NIH/NCI R01CA135038 (to J-MY). Publisher Copyright: {\textcopyright} 2016 Macmillan Publishers Limited, part of Springer Nature.",
year = "2016",
month = dec,
day = "8",
doi = "10.1038/onc.2016.166",
language = "English (US)",
volume = "35",
pages = "6293--6308",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "49",
}